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Background
The main goal of the treatment of neurogenic bladder is to
promote continence and protect the upper urinary tract
from deterioration. Conversion of a hyperreflexic detrusor
to a lower pressure detrusor could be reached by the use
of anticholinergic medication and clean intermittent cath-
eterization (CIC). Important alternative to reduce side
effects and lower the detrusor pressure is the intravesical
administration of oxybutynin. The presented study inves-
tigated the urodynamic effects of the long-term adminis-
tration of intravesical oxybutynin in hyperreflexic
neurogenic bladder to evaluate the property of bladder
auto-augmentation.
Materials and methods
The study included two groups of patients with hyper-
reflexic neurogenic bladder. Group I was treated with CIC
and oral anticholinergic medication, group II with CIC
and intravesical oxybutynin instillation. Urodynamic
assessment was performed before treatment and every fol-
lowing year.
Results
Group I included 9 patients (mean 17.6 years), group II
12 patients (15.8 years). The bladder compliance of 3/9
patients of group I increased to normal values with age
(>10 ml/cmH2O). 6/9 patients of group I responded par-
tially with an increase of bladder compliance. The overall
bladder capacity increased from 177 ml +/- 104 ml up to
367 ml +/- 123 ml in group I. 2/12 patients of group II
stopped the treatment due to side effects. 7/10 patients of
group II increased their bladder compliance up to three
times with age and reached normal values. The bladder
capacity (group II) increased from 148 +/- 61 ml up to 351
+/- 105 ml. 3/10 patients of group II responded only par-
tially with an moderate increase of bladder compliance
(2/10) or no improvement (1/10).
Conclusion
Oral anticholinergic medication and intravesical oxybu-
tynin are effective to increase bladder capacity. Further-
more intravesical oxybutynin also increases bladder
compliance. This leads to diminished bladder pathophys-
iology. Intravesical oxybutynin instillation enables suffi-
cient bladder auto-augmentation in selected patients with
neurogenic hyperreflexic bladder.
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